JP7680433B2 - 抗菌化合物 - Google Patents

抗菌化合物 Download PDF

Info

Publication number
JP7680433B2
JP7680433B2 JP2022516117A JP2022516117A JP7680433B2 JP 7680433 B2 JP7680433 B2 JP 7680433B2 JP 2022516117 A JP2022516117 A JP 2022516117A JP 2022516117 A JP2022516117 A JP 2022516117A JP 7680433 B2 JP7680433 B2 JP 7680433B2
Authority
JP
Japan
Prior art keywords
mmol
compound
alkyl
give
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022516117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548247A5 (https=
JP2022548247A (ja
Inventor
エミリ ジョルジュ ギルモン,ジェローム
マドレーヌ シモーヌ モット,マガリ
アリラ,マリア クリスティナ ビレラ
マリア ジェイ ラマン,ゴドリーブ
ジュリア ドミニク マリア レネ,アデライン
ルドビック ジェンティー,マシュー
アントニー ランプレヒト,ディルク
Original Assignee
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー filed Critical ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Publication of JP2022548247A publication Critical patent/JP2022548247A/ja
Publication of JP2022548247A5 publication Critical patent/JP2022548247A5/ja
Application granted granted Critical
Publication of JP7680433B2 publication Critical patent/JP7680433B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • C07D491/147Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
JP2022516117A 2019-09-13 2020-09-11 抗菌化合物 Active JP7680433B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19197183.7 2019-09-13
EP19197183 2019-09-13
PCT/EP2020/075458 WO2021048342A1 (en) 2019-09-13 2020-09-11 Antibacterial compounds

Publications (3)

Publication Number Publication Date
JP2022548247A JP2022548247A (ja) 2022-11-17
JP2022548247A5 JP2022548247A5 (https=) 2023-09-19
JP7680433B2 true JP7680433B2 (ja) 2025-05-20

Family

ID=67956507

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516117A Active JP7680433B2 (ja) 2019-09-13 2020-09-11 抗菌化合物

Country Status (10)

Country Link
US (1) US20220340564A1 (https=)
EP (1) EP4028399B1 (https=)
JP (1) JP7680433B2 (https=)
CN (1) CN114423758B (https=)
AU (1) AU2020346370B2 (https=)
BR (1) BR112022003799A2 (https=)
CA (1) CA3149868A1 (https=)
ES (1) ES2978573T3 (https=)
MX (1) MX2022003037A (https=)
WO (1) WO2021048342A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348510B (zh) 2015-09-17 2022-01-04 圣母大学 针对分枝杆菌感染有用的含有苄胺的杂环化合物以及组合物
EP4308239A1 (en) * 2021-03-16 2024-01-24 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
IL312366A (en) 2021-10-28 2024-06-01 Janssen Sciences Ireland Unlimited Co Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
EP4296674A1 (en) 2022-06-20 2023-12-27 Université Toulouse III - Paul Sabatier Innovative molecules decreasing virulence of mycobacterium for the treatment of tuberculosis
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025017047A1 (en) 2023-07-18 2025-01-23 Janssen Pharmaceutica Nv Combination products of at least three antibiotics comprising bedaquiline, pretomanid or delamanid, and a cytochrome bc1 inhibitor, and their use in the treatment of mycobacterial infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522253A (ja) 2010-03-18 2013-06-13 インスティチュート・パスツール・コリア 抗感染化合物
JP2015522622A (ja) 2012-07-18 2015-08-06 モラスキ,ギャレット 5,5−ヘテロ芳香族抗感染症化合物
JP2018532723A (ja) 2015-09-17 2018-11-08 ジェー. ミラー,マーヴィン マイコバクテリア感染症に対して有用なベンジルアミン含有複素環化合物及び組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1527050T3 (da) 2002-07-25 2010-07-19 Janssen Pharmaceutica Nv Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
EP2751104B1 (en) 2011-09-01 2019-09-25 Novartis AG Compounds and compositions as c-kit kinase inhibitors
DK3027615T3 (da) 2013-08-02 2021-10-25 Pasteur Institut Korea Antiinfektionsforbindelser
CN105524058B (zh) * 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
BR112017028318B1 (pt) 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
BR112018076126A2 (pt) 2016-06-16 2019-03-26 Janssen Sciences Ireland Unlimited Company compostos heterocíclicos como antibacterianos
MX2018015657A (es) * 2016-06-16 2019-03-14 Janssen Sciences Ireland Unlimited Co Compuestos heterociclico como antibacterianos.
WO2018084809A1 (en) * 2016-11-02 2018-05-11 Nanyang Technological University Methods for the treatment or prevention of mycobacterial infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522253A (ja) 2010-03-18 2013-06-13 インスティチュート・パスツール・コリア 抗感染化合物
JP2015522622A (ja) 2012-07-18 2015-08-06 モラスキ,ギャレット 5,5−ヘテロ芳香族抗感染症化合物
JP2018532723A (ja) 2015-09-17 2018-11-08 ジェー. ミラー,マーヴィン マイコバクテリア感染症に対して有用なベンジルアミン含有複素環化合物及び組成物

Also Published As

Publication number Publication date
CN114423758A (zh) 2022-04-29
KR20220062564A (ko) 2022-05-17
MX2022003037A (es) 2022-04-07
EP4028399C0 (en) 2024-02-14
WO2021048342A1 (en) 2021-03-18
EP4028399A1 (en) 2022-07-20
US20220340564A1 (en) 2022-10-27
CN114423758B (zh) 2025-05-27
AU2020346370B2 (en) 2026-02-12
JP2022548247A (ja) 2022-11-17
ES2978573T3 (es) 2024-09-16
BR112022003799A2 (pt) 2022-05-24
EP4028399B1 (en) 2024-02-14
AU2020346370A1 (en) 2022-05-05
CA3149868A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
JP7680433B2 (ja) 抗菌化合物
AU2022270061B2 (en) Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors
CN115485026A (zh) Nlrp3炎体途径抑制剂吡唑并[1,2-d][1,2,4]三嗪-2-基-乙酰胺
CA3182633A1 (en) 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
JP2023522016A (ja) Nlrp3インフラマソーム経路の阻害剤としてのピラゾロ[1,5-d][1,2,4]トリアジン-5(4h)-アセトアミド
CN107530329A (zh) 用作CDK抑制剂的吡唑并[1,5‑a][1,3,5]三嗪和吡唑并[1,5‑a]嘧啶衍生物
JP2024509998A (ja) 抗菌化合物
CA3220881A1 (en) 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides
CN117580843A (zh) 抗菌化合物
WO2019054430A1 (ja) 芳香族複素環を有するアミド化合物
KR20230152005A (ko) Nlrp3을 조절하는 4-아미노-6-옥소-피리다진 유도체
CA3208988A1 (en) 4-alkoxy-6-oxo-pyridazine derivatives modulating nlrp3
JP2022551823A (ja) 抗菌化合物
CN115667218A (zh) 激酶抑制剂
KR20230157400A (ko) 항박테리아성 화합물
KR102955654B1 (ko) 항균 화합물
CA3236433A1 (en) Tricyclic heterocycles
HK40080567B (en) Antibacterial compounds
HK40080567A (en) Antibacterial compounds
CA3161268C (en) Heterocyclic compounds useful as aurora a selective inhibitors
HK40073265A (zh) 抗细菌化合物
JP2023535932A (ja) 三環式のヘテロ環

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240827

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250508

R150 Certificate of patent or registration of utility model

Ref document number: 7680433

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150